MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

Requestor Name Respondent Name

Memorial Compounding Pharmacy Texas Department of Transportation

MFDR Tracking Number Carrier's Austin Representative

M4-19-2988-01 Box Number 32

MFDR Date Received

January 31, 2019

REQUESTOR'S POSITION SUMMARY

<u>Requestor's Position Summary:</u> "The above claimant received compound medication on **08/01/2018** and are being denied by the carrier for lack of preauthorization. The compound medication does not require preauthorization based on the Rule 134.500."

Amount in Dispute: \$583.89

RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: "Preauthorization was required under Rule 134.530(b)(1)(C)."

Response Submitted by: STONE LOUGHLIN SWANSON

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
August 01, 2018	Compound Medication	\$583.89	\$0.00

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 1. 28 Texas Administrative Codes §134.530(b)(1)(B) and (C) set out preauthorization requirements for compounds not subject to certified health care networks.
- 2. The insurance carrier denied the compound in question based on preauthorization.

<u>Issue</u>

Is reimbursement due for the service in dispute?

Findings

Memorial asserts that preauthorization was not required for the compound in dispute. This compound was dispensed on August 01, 2018. Applicable amended Rule at 28 TAC 134.530 (b)(1)(C) states, in pertinent part, that preauthorization is *only* required for any prescription drug created through compounding prescribed and dispensed on or after July 1, 2018.

According to the adoption preamble, new section (b)(1)(C) **DOES NOT APPLY** to prescriptions for compounded drugs written before July 1, 2018, and refills for those prescriptions. Therefore, for compounds dispensed on or after July 1, 2018, a copy of the physician's initial prescription is necessary for the division to make an informed decision about whether preauthorization is required.

Prior to the filing of this dispute, the division notified Memorial that a copy of the original physician's prescription must be included with all disputes involving compounds dispensed on or after July 1, 2018. In this case, Memorial failed to include the prescription.

Memorial has failed to provide prescription evidence sufficient to support its assertion that preauthorization was not required. Memorial has therefore failed to meet its burden to prove that reimbursement is due.

Conclusion

For the reason stated above, the division finds that the requestor has not established that reimbursement is due. As a result, the amount ordered is \$0.00.

ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031, the division hereby determines the requestor is entitled to \$0.00 additional reimbursement for the services in dispute.

Authorized Signature

		2/28/2019	
Signature	Medical Fee Dispute Resolution Officer	Date	

RIGHT TO APPEAL

Either party to this medical fee dispute may seek review of this division decision. To appeal, submit form division Form-045M titled *Request to Schedule, Reschedule, or Cancel a Benefit Review Conference to Appeal a Medical Fee Dispute Decision (BRC-MFD)* found at https://www.tdi.texas.gov/forms/form20numeric.html.

Follow the instructions on pages 3 and 4. The request must be received by the division within twenty days of your receipt of this decision. This decision becomes final if the request for review of this decision is not timely made.

The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim.

If you have questions about the division Form-045M, please call CompConnection at 1-800-252-7031, Option 3 or you may email your question to CompConnection@tdi.texas.gov

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 1-800-252-7031, Option 1.